Biotech IPO candidate

Investors bet on speciality pharmaceuticals in China

Speciality pharmaceutical company CF PharmTech is looking to raise at least $72 million in funding and has its sights set on an IPO in the near future.

Speciality pharmaceutical company CF PharmTech, which develops inhalation products for illnesses like asthma, is raising at least $72 million in pre-IPO funding, as investors see a profitable future in its treatments for chronic diseases.

The investment is expected to complete in the next few months, and funding will be used to accelerate CF PharmTech’s development. The company is expected to start selling its products in the second half of next year.

CF PharmTech is also planning an IPO in the next one to two years, after its products enter the market.

Established in 2008, the company has more than 20 projects...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222